Takeda Pharmaceutical Company Limited held the grand opening of Takeda Global Headquarters in Tokyo, Japan. The building, completed in March 2018, will serve as Takeda's head office for its operations worldwide.
Thermo Fisher Scientific announced it has signed new agreements with Daiichi Sankyo and Takeda Pharmaceuticals designed to expand the clinical utility of Oncomine Dx Target Test in support of clinical trials and drug development.
Rhythm Pharmaceuticals, a biopharmaceutical company, announced that it has acquired exclusive, worldwide rights from Takeda Pharmaceutical Company to develop and commercialize a rare genetic disorder drug.
TiGenix NV and Takeda announced that the European Commission (EC) has approved Alofisel, previously Cx601, for the treatment of complex perianal fistulas in adult patients with nonactive/mildly active luminal Crohn’s disease.
Takeda, a pharmaceutical company, has developed an innovative sugar-lowering drug that is a combination of alogliptin and metformin. The representatives of the company announced that the drug was launched in the Russian market.
In the near future, the company will localize the manufacturing of several innovative products in Russia. The transfer of manufacturing to Russia will increase the availability of the drug and contribute to reducing its price.